advanced & metastatic gastric cancer
TRANSCRIPT
![Page 1: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/1.jpg)
14/01/15
In The Name Of In The Name Of GodGod
خداوند نام خداوند به نام بهبخشاينده بخشاينده گرگربخشايشبخشايش
![Page 2: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/2.jpg)
Evaluate the combination ofEvaluate the combination of Irinotecan Irinotecan andand Capecitabine Capecitabine in the first line treatment of in the first line treatment of
advanced or metastatic gastric advanced or metastatic gastric cancercancer
Dr.M.DorchinDr.M.DorchinClinical OncologistClinical Oncologist
Dezfol University of Medical SciencesDezfol University of Medical Sciences
![Page 3: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/3.jpg)
BackgroundBackground
Gastric cancerGastric cancer• SecondSecond most common cancer-related death. most common cancer-related death.
• 44thth most common cancer most common cancer• Korea, Japan, China, Taiwan high rates.Korea, Japan, China, Taiwan high rates. with with 875,000875,000 injured annually person in the injured annually person in the
world.world.
![Page 4: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/4.jpg)
Palliative chemotherapy with:Palliative chemotherapy with: Irinotecan and cisplatin.Irinotecan and cisplatin. Folic acid, 5-FU, and irinotecan (Folic acid, 5-FU, and irinotecan (FOLFIRIFOLFIRI).). Leucovorin, 5-FU, and oxaliplatin (Leucovorin, 5-FU, and oxaliplatin (FOLFOXFOLFOX).).
Phase II Phase II studies evaluating studies evaluating irinotecan-basedirinotecan-based or or oxaliplatin-basedoxaliplatin-based regimens demonstrate regimens demonstrate similar responsesimilar response rates rates
Treatment options under clinical evaluation:
![Page 5: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/5.jpg)
Second-Line Therapy in Gastric CancerSecond-Line Therapy in Gastric Cancer
** 20-40% patients receiving 1 20-40% patients receiving 1stst-line -line therapy receive 2therapy receive 2ndnd-line-line
** Taxanes(weekly paclitaxel)and Irinotecan most commonly used 2nd-line therapy…..
![Page 6: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/6.jpg)
Progression Free SurvivalProgression Free Survival
)Months(
Pro
bab
ilit
y )
%(
2 .33.6
108111
6646
1618
98
36
22
wPTXIRI
Number at risk
21
00
00
IRI
wPTX
n
111
108
Median
2.3M
3.6M
P
0.33
HR (95% CI(
1.14( 0.88-1.49)
Log-rank test
FAS
IRI150 mg/m2 d1, 15 q4w
weekly Paclitaxel80 mg/m2 d1, 8, 15 q4w
![Page 7: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/7.jpg)
Irinotecan vs. Best Supportive Care in Second-line Gastric Cancer
Thuss-Patience et al. ASCO 2013
Irinotecan 250 mg/m2Irinotecan 250 mg/m2 q 3weeks
Best Supportive CareBest Supportive Care
MedianMedian SurvivalSurvival
4.1 mo
2.4 mo
P = 0.02P = 0.02HR = 0.48 (95% CI, 0.25-0.92HR = 0.48 (95% CI, 0.25-0.92((
NN21
19
![Page 8: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/8.jpg)
Fig. 2 Overall survival (intention to treat population) Median survival Irinotecan: 4.0 months, BSC: 2.4 months; one sided logrank test: p =
0.012; HR: 0.48 (95% CI: 0.25–0.92).
Peter C. Thuss-Patience , Albrecht Kretzschmar , Dmitry Bichev , Tillman Deist , Axel Hinke , Kirstin Breithaupt ,...European Journal of Cancer, Volume 47, Issue 15, 2011, 2306 - 2314
AIO: Small trial of irinotecan vs BSC
![Page 9: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/9.jpg)
INCREASED EFFICACYINCREASED EFFICACY
Compatible side effects
Different mechanisms of resistance
ACTIVITYACTIVITY SAFETYSAFETY
Aim of combination therapy
Different mechanisms of action
![Page 10: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/10.jpg)
![Page 11: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/11.jpg)
Patients & methodsPatients & methods:: The size of the sample assessed The size of the sample assessed 849849 patients, patients,
and has been started accepting patients in and has been started accepting patients in SyriaSyria (Damascus) in July of (Damascus) in July of 2007, and begin accepting , and begin accepting patients at the Center for patients at the Center for Al-BairouniAl-Bairouni UniversityUniversity HospitalHospital in June of in June of 2009, and , and ended up accepting patients in December of ended up accepting patients in December of 2011, and from scheduled follow-up of patients , and from scheduled follow-up of patients follow-up up to follow-up up to two yearstwo years..
![Page 12: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/12.jpg)
Statistical AnalysesStatistical AnalysesTable 1 shows total new cancer cases referred to the Al-Bairouni Table 1 shows total new cancer cases referred to the Al-Bairouni
hospital from 2007-2009hospital from 2007-2009::
Year New cases
GI cancer patients
Gastric cancer
Percentage
2007 9058 758 218 2.4%
2008 9774 874 289 2.9%
2009 10323 963 342 3.3%
07 - 09 29155 2595 849 2.9%
![Page 13: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/13.jpg)
Al-Bairouni University HospitalAl-Bairouni University Hospital
![Page 14: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/14.jpg)
Method:Method:
Irinotecan 180mg/m2 IV d1 Irinotecan 180mg/m2 IV d1
Capecitabine (Xeloda) 1000 mg/m2Capecitabine (Xeloda) 1000 mg/m2
orally bid d1-14orally bid d1-14
Repeat cycle every 3 weeks for 6 cycles.Repeat cycle every 3 weeks for 6 cycles.
![Page 15: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/15.jpg)
Monitoring follow-upMonitoring follow-up:: Text of the protocol to conduct Text of the protocol to conduct clinical clinical
examinationexamination, and a full assessment, the patient , and a full assessment, the patient responsive to treatment, and responsive to treatment, and every three months after the end of treatment, while the after the end of treatment, while the remaining patients, is up to watch them, and remaining patients, is up to watch them, and assess their condition, when they visit the assess their condition, when they visit the hospital, and in order to hospital, and in order to assessassess the the survival survival CollegeCollege..
![Page 16: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/16.jpg)
Age DistributionAge Distribution
![Page 17: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/17.jpg)
Geographic DistributionGeographic Distributionprovince patient percentage
Damascus 390 41%
Countryside of Damascus
118 13%
Aleppo 115 13%
Homs 87 9%
Dar,a 59 6%
Lattaquieh 58 6%
Hom,a 8 3%
Tartoos 5 3%
Al-Reke 5 3%
Al-Sowida 4 3%
Total 849 100%
Results
390
118115
87
59
58
8%5 5 4
θ Ωϖ ϣ
έϒϳθ Ωϖ ϣ
ΐ ΣϠ
κ ΣϤ
ΎϋέΩ
Δ Ϋϴϗϻ
ΓΎΣϤ
α ρήρϮ
Δήϗϟ
Ϊ δ ϳϮ ϟ
The most patients were from Damascus and Aleppo provinces and seaboard patients were the less.
![Page 18: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/18.jpg)
Family HistoryFamily HistoryFamily History Patient Percentage
F.H positive 51 6%
F.H negative 798 94%
Total 849 100%
![Page 19: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/19.jpg)
Smoking & AlcoholismSmoking & Alcoholism
Smoking Patient Percentage
smoker 688 81%
No smoker
160 19%
Total 849 100%
Alcohol user
Patient Percentage
Alcoholism 101 12%
Non Alcoholism
748 88%
Total 849 100%
![Page 20: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/20.jpg)
![Page 21: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/21.jpg)
![Page 22: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/22.jpg)
![Page 23: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/23.jpg)
![Page 24: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/24.jpg)
![Page 25: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/25.jpg)
![Page 26: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/26.jpg)
Presented by intern 張家維
![Page 27: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/27.jpg)
ConclusionConclusion::
Participation is therapeutic, which combines Participation is therapeutic, which combines both of the following drugs :both of the following drugs :
irinotecanirinotecan, and , and CapecitabineCapecitabine, treatment , treatment plans of the most promising in the treatment of plans of the most promising in the treatment of advanced cancer of the stomach or in transition, advanced cancer of the stomach or in transition, where the response rate was recordedwhere the response rate was recorded
objective response is goodobjective response is good & & acceptable side effects well-toleratedacceptable side effects well-tolerated..
![Page 28: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/28.jpg)
Dr.HossamDr.Hossam(Head of Damascus Cancer Center)(Head of Damascus Cancer Center) Dr.Chams-addinDr.Chams-addin(Head of GI Center)(Head of GI Center) Dr.Majdi-ZinDr.Majdi-Zin(Head of Radiation Oncology Center)(Head of Radiation Oncology Center)
Our Group Our Group Al-BairouniAl-Bairouni cancer center cancer center
Damascus University Damascus University
![Page 29: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/29.jpg)
ReferencesReferences::
Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev 1 (4): 285-304, 1974. [PUBMED Abstract]melanoma. Cancer Treat Rev 1 (4): 285-304, 1974. [PUBMED Abstract]
Cullinan SA, Moertel CG, Fleming TR, et al.: A comparison of three chemotherapeutic regimens in the treatment of Cullinan SA, Moertel CG, Fleming TR, et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253 (14): 2061-7, 1985. [PUBMED Abstract]and mitomycin. JAMA 253 (14): 2061-7, 1985. [PUBMED Abstract]
Ohtsu A, Shimada Y, Shirao K, et al.: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin Ohtsu A, Shimada Y, Shirao K, et al.: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (1): 54-9, 2003. [PUBMED Abstract]Oncology Group Study (JCOG9205). J Clin Oncol 21 (1): 54-9, 2003. [PUBMED Abstract]
Waters JS, Norman A, Cunningham D, et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric Waters JS, Norman A, Cunningham D, et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80 (1-2): 269-72, 1999. [PUBMED Abstract]cancer: results of a randomized trial. Br J Cancer 80 (1-2): 269-72, 1999. [PUBMED Abstract]
Ross P, Nicolson M, Cunningham D, et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted Ross P, Nicolson M, Cunningham D, et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 (8): 1996-2004, 2002. [PUBMED Abstract]Clin Oncol 20 (8): 1996-2004, 2002. [PUBMED Abstract]
![Page 30: Advanced & Metastatic Gastric Cancer](https://reader030.vdocuments.mx/reader030/viewer/2022032421/55a758261a28ab1a378b45dd/html5/thumbnails/30.jpg)
Thanks For Your Kindly AttentionThanks For Your Kindly Attention